Pharmaceutical Treatment for Heart Failure

Area of Science:

• Cardiology and Pharmacology
• Clinical Medicine

Background:

• Heart failure (HF) is a critical clinical syndrome due to impaired ventricular function.
• HF is categorized into HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), and HF with midrange ejection fraction (HFmrEF).
• Despite progress in HFrEF treatment, HF remains a fatal condition with unmet needs, particularly for HFpEF.

Purpose of the Study:

• To review current pharmaceutical management strategies for acute and chronic heart failure.
• To summarize major clinical trials in heart failure pharmacotherapy.
• To discuss emerging drug candidates and the potential of Traditional Chinese Medicine in HF treatment.

Main Methods:

• Literature review of current advances in pharmaceutical management for heart failure.
• Summary of key clinical trials for different heart failure classifications.
• Inclusion of information on novel therapeutic agents and complementary medicine approaches.

Main Results:

• Significant advances have been made in treating HFrEF.
• Current pharmaceutical options address acute HF and disease progression.
• There remains a notable deficiency in effective treatments for HFpEF.

Conclusions:

• The review highlights progress in heart failure pharmacotherapy, especially for HFrEF.
• Further research is crucial for developing novel treatments, particularly for HFpEF.
• Traditional Chinese Medicine presents a potential avenue for future HF therapies.